Likewise, NCT04188548, a Phase 1a/1b study in which LY3484356, an oral selective estrogen receptor degrader (SERD), is administered as a monotherapy and in combination with anticancer therapies (aromatase inhibitor, abemaciclib, alpelisib, everolimus, trastuzumab, and pertuzumab) for patients with ER positive locally advanced or metastatic breast cancer or endometrial cancer (EMBER, phase 1a/1b). Here, ESR1 is linked to endometrial cancer.